Kurzfassung

A phase 2/3, multicenter, randomized, double-blinded, placebo-controlled, repeat dose, dose-comparison study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of olipudase alfa in patients with acid shingomyelinase deficiency
(Phase 2/3 klinische Studie)